These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15645133)

  • 1. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin.
    Merimsky O; Hirsh L; Dantes A; Land-Bracha A; Suh BS; Amsterdam A
    Int J Oncol; 2005 Feb; 26(2):475-82. PubMed ID: 15645133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors as anti-cancer drugs.
    Hirsh L; Dantes A; Suh BS; Yoshida Y; Hosokawa K; Tajima K; Kotsuji F; Merimsky O; Amsterdam A
    Biochem Pharmacol; 2004 Sep; 68(6):981-8. PubMed ID: 15313391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299).
    Crescenzi E; Chiaviello A; Canti G; Reddi E; Veneziani BM; Palumbo G
    Mol Cancer Ther; 2006 Mar; 5(3):776-85. PubMed ID: 16546993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene.
    Yoshida Y; Hosokawa K; Dantes A; Tajima K; Kotsuji F; Amsterdam A
    Int J Oncol; 2000 Aug; 17(2):227-35. PubMed ID: 10891529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
    Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
    Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
    Kim MK; Jeon YK; Woo JK; Choi Y; Choi DH; Kim YH; Kim CW
    Mol Cancer; 2011 Aug; 10():98. PubMed ID: 21843371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
    Cao W; Yang Q; Yuan Z; Li H; Wang W; Xiao X; Wang Z; Liang L; Zhou P; Liu J; Hu X; Zhang B
    Biochem Biophys Res Commun; 2020 Apr; 524(3):549-554. PubMed ID: 32014255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
    Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
    Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
    Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.
    Ferreira CG; Span SW; Peters GJ; Kruyt FA; Giaccone G
    Cancer Res; 2000 Dec; 60(24):7133-41. PubMed ID: 11156422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
    Srirangam A; Milani M; Mitra R; Guo Z; Rodriguez M; Kathuria H; Fukuda S; Rizzardi A; Schmechel S; Skalnik DG; Pelus LM; Potter DA
    J Thorac Oncol; 2011 Apr; 6(4):661-70. PubMed ID: 21270666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.
    Han JY; Hong EK; Choi BG; Park JN; Kim KW; Kang JH; Jin JY; Park SY; Hong YS; Lee KS
    Med Oncol; 2003; 20(4):355-62. PubMed ID: 14716031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.